Invivyd Inc. (IVVD) - Total Liabilities
Based on the latest financial reports, Invivyd Inc. (IVVD) has total liabilities worth $38.69 Million USD as of March 2026. Total liabilities represent everything the company owes to external parties, combining both current liabilities—like accounts payable, short-term debt, and accrued expenses—and non-current liabilities such as long-term debt, pension obligations, lease liabilities, and deferred tax liabilities.
Invivyd Inc. - Total Liabilities Trend (2020–2025)
This chart illustrates how Invivyd Inc.'s total liabilities have evolved over time, based on quarterly financial data. See IVVD current assets to equity ratio to evaluate short-term liquidity relative to the company's equity base.
Invivyd Inc. Competitors by Total Liabilities
The table below lists competitors of Invivyd Inc. ranked by their total liabilities.
| Company | Country | Total Liabilities |
|---|---|---|
|
Stack Capital Group Inc
TO:STCK
|
Canada | CA$13.20 Million |
|
Infinity Natural Resources, Inc.
NYSE:INR
|
USA | $1.10 Billion |
|
8x8 Inc Common Stock
NASDAQ:EGHT
|
USA | $518.66 Million |
|
Elnusa Tbk
JK:ELSA
|
Indonesia | Rp5.60 Trillion |
|
AC IMMUNE SA SF-02
F:IMR
|
Germany | €105.89 Million |
|
Guangdong Jiaying Pharmaceutical Co Ltd
SHE:002198
|
China | CN¥162.39 Million |
|
Global Tax Free Co. Ltd
KQ:204620
|
Korea | ₩53.72 Billion |
|
VNV Global AB
ST:VNV
|
Sweden | Skr91.18 Million |
Liability Composition Analysis (2020–2025)
This chart breaks down Invivyd Inc.'s total liabilities into key components over time: long-term debt, short-term debt, other current liabilities, and other non-current liabilities. Toggle between absolute values and percentage view to see how the composition has shifted. For the full company profile including market capitalisation, see Invivyd Inc. market cap and net worth.
Liquidity & Leverage Metrics
Key Metrics Explained
| Metric | Value | Description |
|---|---|---|
| Current Ratio | 6.47 | Measures ability to pay short-term obligations (Current Assets ÷ Current Liabilities) |
| Quick Ratio | N/A | More stringent measure of short-term liquidity ((Current Assets - Inventory) ÷ Current Liabilities) |
| Cash Ratio | N/A | Most conservative liquidity measure (Cash & Equivalents ÷ Current Liabilities) |
| Debt to Equity | 0.19 | Measures financial leverage (Total Liabilities ÷ Shareholder Equity) |
| Debt to Assets | 0.16 | Portion of assets financed with debt (Total Liabilities ÷ Total Assets) |
Liability Trends Comparison
This chart compares key liability metrics across different time periods, showing how Invivyd Inc.'s debt structure has evolved. The comparison includes total liabilities, long-term debt, and current liabilities.
Annual Total Liabilities for Invivyd Inc. (2020–2025)
The table below shows the annual total liabilities of Invivyd Inc. from 2020 to 2025.
| Year | Total Liabilities | Change |
|---|---|---|
| 2025-12-31 | $35.34 Million | -42.97% |
| 2024-12-31 | $61.98 Million | +19.85% |
| 2023-12-31 | $51.71 Million | +90.14% |
| 2022-12-31 | $27.20 Million | -56.18% |
| 2021-12-31 | $62.07 Million | -66.01% |
| 2020-12-31 | $182.63 Million | -- |
About Invivyd Inc.
Invivyd, Inc., together with its subsidiaries, engages in the research, development, commercialization, and sale of antibody therapies for the prevention and treatment of viral infectious diseases in the United States. The company offers Pemivibart, a half-life extended investigational monoclonal antibody for the pre-exposure prophylaxis prevention of COVID-19 in adults and adolescents through in… Read more